Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rusfertide Extension in Beta-Thalassemia
NCT04054921Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of rusfertide in beta thalassemia, sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Proportion of subjects with side effects and severity of side effects at 2 years. Started May 2019; status: completed.
02
Drugs
rusfertide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04054921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054921.